Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Pres. Rsrch & Cf. Sctific Ofcr | April 14, 2023 | April 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUTRO BIOPHARMA, INC.
Report date April 14, 2023 · Filed April 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,368 |
Ending reported balance
After 2023-04-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-04-14 · Exercise / conversion · Acquired 3,750 · Balance 101,664 Row 2 · 2023-04-14 · Tax withholding · Disposed 1,296 · Balance 100,368 F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2025-04-16 | Direct | 7,500 |
Reported balance
After 2023-04-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-04-14 · Exercise / conversion · Disposed 3,750 · Balance 7,500 F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3: The RSUs vest as to 1/4th of the total shares annually beginning on April 16, 2022, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.
F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F3: The RSUs vest as to 1/4th of the total shares annually beginning on April 16, 2022, subject to continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2020 Filed Oct 6, 2020 16:54 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 9,182 | $4.36 | $40,033.52 |
DisclosureSEC source: 0001209191-20-054025 · doc4.xml · nonDerivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 28, 2020 Filed Sep 28, 2020 17:55 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | SaleCommon Stock | 975 | $10.26 | $10,006.72 |
DisclosureSEC source: 0001209191-20-052246 · doc4.xml · nonDerivative · entry 5 Hallam Trevor · CIK 0001326592 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,530 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.16 to $10.41 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:55 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 6,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052246 · doc4.xml · derivative · entry 7 Hallam Trevor · CIK 0001326592 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,887 shares Expires 2020-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The RSUs vest as to 1/2 of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:55 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 11,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052246 · doc4.xml · derivative · entry 6 Hallam Trevor · CIK 0001326592 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,019 Underlying: Common Stock · 11,019 shares Expires 2021-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:55 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,381 | $10.30 | $24,524.30 |
DisclosureSEC source: 0001209191-20-052246 · doc4.xml · nonDerivative · entry 4 Hallam Trevor · CIK 0001326592 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,505 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:55 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 6,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052246 · doc4.xml · nonDerivative · entry 3 Hallam Trevor · CIK 0001326592 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:55 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,810 | $10.30 | $39,243.00 |
DisclosureSEC source: 0001209191-20-052246 · doc4.xml · nonDerivative · entry 2 Hallam Trevor · CIK 0001326592 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,999 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:55 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 11,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052246 · doc4.xml · nonDerivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2020 Filed Aug 27, 2020 17:04 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | SaleCommon Stock | 975 | $9.04 | $8,818.29 |
DisclosureSEC source: 0001209191-20-048538 · doc4.xml · nonDerivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,790 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.85 to $9.31 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 27, 2020 Filed Jul 28, 2020 17:08 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | SaleCommon Stock | 975 | $8.06 | $7,858.21 |
DisclosureSEC source: 0001209191-20-043857 · doc4.xml · nonDerivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,765 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.02 to $8.28 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 26, 2020 Filed Jun 29, 2020 19:23 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | SaleCommon Stock | 975 | $8.02 | $7,817.65 |
DisclosureSEC source: 0001209191-20-039220 · doc4.xml · nonDerivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,740 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.81 to $8.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 26, 2020 Filed May 27, 2020 18:38 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | SaleCommon Stock | 975 | $10.00 | $9,753.32 |
DisclosureSEC source: 0001209191-20-032414 · doc4.xml · nonDerivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,715 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.84 to $10.145 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 27, 2020 Filed Apr 27, 2020 20:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | SaleCommon Stocck | 2 | $11.19 | $22.38 |
DisclosureSEC source: 0001209191-20-025882 · doc4.xml · nonDerivative · entry 2 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,690 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. Read SEC document |
| April 27, 2020 Filed Apr 27, 2020 20:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | SaleCommon Stock | 973 | $9.41 | $9,160.50 |
DisclosureSEC source: 0001209191-20-025882 · doc4.xml · nonDerivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,692 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.20 to $9.59 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 26, 2020 Filed Mar 27, 2020 17:32 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | SaleCommon Stock | 975 | $9.69 | $9,452.53 |
DisclosureSEC source: 0001209191-20-021438 · doc4.xml · nonDerivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,665 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.34 to $9.885 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 17:34 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | SaleCommon Stock | 975 | $10.47 | $10,207.28 |
DisclosureSEC source: 0001209191-20-013478 · doc4.xml · nonDerivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,640 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.13 to $10.75 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 17:17 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005810 · doc4.xml · derivative · entry 2 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2024-01-29 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 17:17 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 47,500 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001209191-20-005810 · doc4.xml · derivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2030-01-29 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 29, 2020, with 100% of the total shares vested and exercisable on January 29, 2024, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 16:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | SaleCommon Stock | 975 | $10.51 | $10,250.37 |
DisclosureSEC source: 0001209191-20-005159 · doc4.xml · nonDerivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,615 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.42 to $10.81 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 26, 2019 Filed Dec 27, 2019 17:31 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | SaleCommon Stock | 975 | $11.08 | $10,802.22 |
DisclosureSEC source: 0001209191-19-062036 · doc4.xml · nonDerivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,590 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.83 to $11.29 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 16:50 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | SaleCommon Stock | 975 | $10.68 | $10,410.27 |
DisclosureSEC source: 0001209191-19-058353 · doc4.xml · nonDerivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,565 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.49 to $10.79 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 28, 2019 Filed Oct 30, 2019 20:19 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | SaleCommon Stock | 975 | $9.98 | $9,726.11 |
DisclosureSEC source: 0001209191-19-054572 · doc4.xml · nonDerivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,540 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.44 to $10.11 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:23 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 6,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051119 · doc4.xml · derivative · entry 6 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,887 Underlying: Common Stock · 6,887 shares Expires 2020-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/2 of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:23 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 11,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051119 · doc4.xml · derivative · entry 5 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,038 Underlying: Common Stock · 11,019 shares Expires 2021-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:23 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,381 | $9.74 | $23,190.94 |
DisclosureSEC source: 0001209191-19-051119 · doc4.xml · nonDerivative · entry 4 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,515 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:23 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 6,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051119 · doc4.xml · nonDerivative · entry 3 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:23 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,810 | $9.74 | $37,109.40 |
DisclosureSEC source: 0001209191-19-051119 · doc4.xml · nonDerivative · entry 2 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,009 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:23 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 11,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051119 · doc4.xml · nonDerivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:08 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 47,500 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-19-006203 · doc4.xml · derivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 28, 2019, with 100% of the total shares vested and exercisable on January 29, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionSeries D Preferred Stock · Derivative | 50,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052837 · doc4.xml · derivative · entry 2 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,026 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended, and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended, and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended, and had no expiration date. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionCommon Stock | 2,026 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052837 · doc4.xml · nonDerivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended, and had no expiration date. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 17:55 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 13,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052482 · doc4.xml · derivative · entry 3 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,774 Underlying: Common Stock · 13,774 shares Expires 2020-09-25 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/2 of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 17:55 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 33,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052482 · doc4.xml · derivative · entry 2 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,057 Underlying: Common Stock · 33,057 shares Expires 2021-09-25 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 17:55 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 198,347 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052482 · doc4.xml · derivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,347 Underlying: Common Stock · 198,347 shares Expires 2028-09-25 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on October 26, 2018, with 100% of the total shares vested and exercisable on September 26, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.